Hobbs Kallie J, Le Sueur Andre N V, Burke Megan J, Cooper Bethanie L, Sheats M Katie, Ueda Yu
Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, United States.
Front Vet Sci. 2024 May 14;11:1414426. doi: 10.3389/fvets.2024.1414426. eCollection 2024.
Develop, implement, and monitor for adverse effects of, a novel hemoperfusion therapy in adult horses.
A prospective, observational feasibility study using three healthy adult horses from the North Carolina State University teaching herd. Health status was determined by physical exam, complete blood count, coagulation panel, and serum biochemistry. Each horse was instrumented with a 14 Fr × 25 cm double-lumen temporary hemodialysis catheter and underwent a 240 min polymer-based hemoperfusion session. Horses were administered unfractionated heparin to maintain anti-coagulation during the session. Given the novelty of this therapy in horses, each horse was treated as a learning opportunity that informed an iterative process of protocol development and modification.
Our long-term goal is to investigate potential clinical applications of hemoperfusion in horses, including cytokine reduction in horses with severe SIRS/sepsis. Horses were monitored for changes in clinical exam, biochemistry and hematology parameters. Additionally, cytokines were quantified to determine whether extracorporeal hemadsorption therapy alone caused an inflammatory response. Our results show that hemoperfusion therapy was associated with decreased platelet counts and serum albumin concentration. There was no significant change in plasma cytokine concentrations with hemoperfusion therapy. In one horse, the cytokine concentrations decreased, as previously reported with hemoperfusion therapy in humans.
We hypothesized that hemoperfusion therapy could be performed in healthy adult horses without significant adverse effects.
Polymer-based hemoperfusion is a feasible extracorporeal therapy (ECT) modality for adult horses. Additional studies are needed to further establish clinical protocols, as well as establish efficacy of polymer-based hemoperfusion for treatment of various conditions in horses, including intoxications, immune-mediated conditions, and sepsis.
开发、实施并监测一种针对成年马的新型血液灌流疗法的不良反应。
一项前瞻性观察性可行性研究,使用来自北卡罗来纳州立大学教学马群的3匹健康成年马。通过体格检查、全血细胞计数、凝血指标和血清生化检查来确定健康状况。每匹马都植入一根14Fr×25 cm的双腔临时血液透析导管,并进行240分钟的基于聚合物的血液灌流治疗。在治疗过程中给马注射普通肝素以维持抗凝状态。鉴于这种疗法在马身上的新颖性,每匹马都被视为一个学习机会,为方案制定和修改的迭代过程提供信息。
我们的长期目标是研究血液灌流在马身上的潜在临床应用,包括降低重症全身炎症反应综合征/脓毒症马匹的细胞因子水平。监测马匹的临床检查、生化和血液学参数的变化。此外,对细胞因子进行定量,以确定单独的体外血液吸附疗法是否会引起炎症反应。我们的结果表明,血液灌流疗法与血小板计数和血清白蛋白浓度降低有关。血液灌流疗法后血浆细胞因子浓度没有显著变化。在一匹马中,细胞因子浓度降低,正如之前人类血液灌流疗法的报道。
我们假设在健康成年马中可以进行血液灌流疗法且无明显不良反应。
基于聚合物的血液灌流是成年马可行的体外治疗(ECT)方式。需要进一步的研究来进一步制定临床方案,并确定基于聚合物的血液灌流对治疗马的各种病症(包括中毒、免疫介导病症和脓毒症)的疗效。